common.study.topics.clinical

Testing Experimental Medication in Healthy Subjects

common.study.values.description

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

The pharmacokinetics of a single dose of pexidartinib will be investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Pexidartinib

Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.

participant.views.study.view.additional

participant.views.study.view.scientific-title

An Open-label, Single-dose Study to Assess the Pharmacokinetics of Pexidartinib in Subjects With Moderate Hepatic Impairment Compared to Healthy Subjects

common.study.values.clinical-trial-id

NCT04223635

participant.views.study.view.id

erkjka